Foreign investors acquired seven companies listed on London's Alternative Investment Market during the first six months of 2026, paying an average premium of 62 per cent above prevailing share prices as international buyers exploit depressed UK stock valuations and a weak pound.
Research published in a half-year stocktake by broker Allenby Capital shows that American buyers orchestrated six of the seven completed transactions. An additional six AIM-quoted companies remain under formal offer, taking the total value of businesses leaving or set to leave the market to approximately £2.3 billion as corporate boards routinely accept acquisition offers rather than mount defensive campaigns.
The Alternative Investment Market, established by the London Stock Exchange to assist smaller and growing businesses in raising capital, saw its total roster of listed companies fall to 605. During the six-month period, 30 firms departed the index while only 16 joined. By comparison, AIM routinely attracted approximately 70 new company listings per year during the 2010s.
Total capital raised on the market reached £3.1 billion over the half-year period. However, £1.9 billion of that figure was accounted for by Rosebank Industries, which subsequently transferred its listing to the Main Market of the London Stock Exchange. Despite the shrinking number of listings, trading volume rose 21 per cent, with market liquidity holding at 3.9 per cent.
Market commentator Ian Lyall noted that the trend reflects growing vulnerability among UK growth businesses, which remain vulnerable to overseas acquisition while stock valuations remain subdued.
Subdued Week for London Stock Indices
The AIM All-Share index closed the trading week 0.6 per cent higher at 807.39 during a quiet summer trading period. The modest advance allowed the junior market to outperform its primary benchmark, the FTSE 100 index of major British public companies, which traded sideways over the mid-summer holiday period.
Energy and Mining Stocks Drive Gains
GCM Resources recorded the largest gain of the week on the AIM board, soaring 240 per cent. The resource explorer holds a single primary asset, a massive coal seam located under Phulbari in Bangladesh, which has remained undeveloped for more than a decade while awaiting government regulatory approval.
The share price surge followed remarks by Bangladesh's finance minister to a business audience in Dhaka. The minister stated that the government was evaluating the inclusion of coal within its national energy mix and reportedly discussed open-pit mining, a surface extraction method required to develop the Phulbari project. GCM Resources issued a cautious statement welcoming the minister's comments while noting that no formal contractual agreement or project approval had been granted.
Shares in AOTI jumped 38 per cent despite a lack of formal corporate announcements explaining the movement. The company's sole regulatory filing disclosed that three company executives purchased a total of 2,766 shares through a staff share scheme, representing a combined transaction value of less than £3,000.
Sabien Technology rose 36 per cent after confirming ongoing negotiations with SaveMoneyCutCarbon regarding a UK distribution agreement for its M2G energy-saving system. The company clarified that no contract has been signed. Additionally, Sabien abandoned a proposed £2 million convertible loan note, eliminating potential share dilution risks, while director Richard Parris maintained his equity stake and backing.
Thor Energy gained 33 per cent during the quiet trading session. The movement preceded a scheduled presentation by managing director Andrew Hume regarding natural hydrogen and helium exploration at an upcoming Australian petroleum industry conference.
Administrative Delays and Exploration Results
Exploration firm Jangada Mines fell 17 per cent following the release of initial phase 1 drilling results from its Molly Gold Project. Although assays revealed high gold concentrations, including rock chip samples returning up to 306 grams of gold per tonne at the Vivi target, investor selling persisted alongside corporate assurances regarding the company's financial position.
eEnergy Group dropped 17 per cent after reporting payment delays involving approximately £3.2 million owed for completed work on its 65-site Mace project. The company stated that the payment delays were caused by outstanding administrative paperwork, primarily concerning solar photovoltaic installations.
Cancer Vaccine Breakthrough Boosts Rivals
British biotechnology company Scancell gained indirect support following positive clinical trial data reported by pharmaceutical firms Moderna and Merck. Moderna and Merck announced that their experimental melanoma vaccine successfully passed its final major clinical trial, causing shares in Moderna to rise 150 per cent.
Both companies are developing therapeutic cancer vaccines designed to train the human immune system to identify and destroy cancer cells. While Moderna's treatment requires customized manufacturing tailored to individual patients, making it complex and expensive, Scancell is developing an off-the-shelf vaccine designed for standardized administration at lower cost.
Stockbroker Panmure Liberum stated that Scancell's manufacturing model could provide a commercial advantage. Scancell recently received regulatory approval from UK authorities to commence its own final-stage clinical trials later this year.
